Serena shows tender side by meeting young cancer sufferer Reuters LONDON (Reuters) – Serena Williams displayed her tender side again on Thursday when she spoke of her meeting with five-year-old cancer sufferer Jack Marshall during this year's championship. "I kind of met him on Twitter. … Serena Williams wonders why she, Venus get Court 2San Jose Mercury News
Serena Williams wonders why she, Venus get Court 2Seattle Post Intelligencer Serena Williams Defeats Halep to Reach Wimbledon Third RoundBloomberg CNN International -The Guardian -ESPN all 472 news articles »
American Idol Alumni Pitch In To Benefit Cancer Support Group Seattle Post Intelligencer One of the most memorable finalists in American Idol's 10-year history, Sanjaya Malakar, will be a featured performer at the event. Hot on the heels of his newly released single, Malakar will close the show and be accompanied by his band. …
Cyclacel’s CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
Amgen to buy experimental cancer drug maker Biovex in $1bn deal
Amgen, the world’s largest biotechnology company, said it agreed to buy Biovex, a closely-held maker of experimental cancer drugs for $425m plus as much as $575m in milestone payments.
Oncolytics Biotech Harnesses Human Reovirus in Battle Against Colorectal Cancer
Enrollment for a Phase I study is open for patients with a form of colorectal cancer, where the patients will be treated with a cancer biologic called REOLYSIN
Positive Phase II Results With Iniparib (BSI-201) In Women With Metastatic Triple Negative Breast Cancer
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine (NEJM) published the final phase II data for the investigational drug iniparib* (BSI-201) demonstrating significant clinical benefit in women with metastatic triple negative breast cancer (mTNBC) when iniparib was administered in combination with …
Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer
Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.
